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Abstract
Cocoa ﬂavanol (CF) intake improves endothelial function in patients with cardiovascular risk factors and disease. We investigated the effects of
CF on surrogate markers of cardiovascular health in low risk, healthy, middle-aged individuals without history, signs or symptoms of CVD. In a
1-month, open-label, one-armed pilot study, bi-daily ingestion of 450 mg of CF led to a time-dependent increase in endothelial function
(measured as ﬂow-mediated vasodilation (FMD)) that plateaued after 2 weeks. Subsequently, in a randomised, controlled, double-masked,
parallel-group dietary intervention trial (Clinicaltrials.gov: NCT01799005), 100 healthy, middle-aged (35–60 years) men and women consumed
either the CF-containing drink (450 mg) or a nutrient-matched CF-free control bi-daily for 1 month. The primary end point was FMD.
Secondary end points included plasma lipids and blood pressure, thus enabling the calculation of Framingham Risk Scores and pulse wave
velocity. At 1 month, CF increased FMD over control by 1·2 % (95 % CI 1·0, 1·4 %). CF decreased systolic and diastolic blood pressure by
4·4mmHg (95 % CI 7·9, 0·9 mmHg) and 3·9 mmHg (95 % CI 6·7, 0·9 mmHg), pulse wave velocity by 0·4 m/s (95 % CI 0·8, 0·04 m/s), total
cholesterol by 0·20 mmol/l (95 % CI 0·39, 0·01 mmol/l) and LDL-cholesterol by 0·17 mmol/l (95 % CI 0·32, 0·02 mmol/l), whereas HDL-
cholesterol increased by 0·10 mmol/l (95 % CI 0·04, 0·17 mmol/l). By applying the Framingham Risk Score, CF predicted a signiﬁcant lowering
of 10-year risk for CHD, myocardial infarction, CVD, death from CHD and CVD. In healthy individuals, regular CF intake improved accredited
cardiovascular surrogates of cardiovascular risk, demonstrating that dietary ﬂavanols have the potential to maintain cardiovascular health even
in low-risk subjects.
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Flavanols, a subgroup of dietary plant-derived bioactives, have
gained increasing attention, as clinical studies have shown that a
higher intake of ﬂavanol-containing foods can improve arterial
function in individuals at risk for CVD and with established
CVD(1,2). The mechanisms of action underlying the biological
effects of ﬂavanols are not completely understood. However,
ﬂavanols are one of the few bioactives known today, for which
causality between intake and an improvement in arterial function
has been formally demonstrated(3). A recent meta-analysis of
forty-two randomised controlled human dietary intervention
studies also demonstrated signiﬁcant acute and chronic (up to
18 weeks) ﬂavanol-dependent cardiovascular beneﬁts(4,5). The
observed cardiovascular beneﬁts include the recovery of endo-
thelial function, a decrease in blood pressure (BP) and
improvements in lipids and insulin resistance(6). For the most
part, these effects have been studied in individuals at increased
cardiovascular risk, such as smokers, or those with established
hypertension, diabetes, hypercholesterolaemia and manifest
coronary artery disease(4,5).
Whether or not the intake of cocoa ﬂavanol (CF) has the
potential to maintain and/or improve cardiovascular health in
individuals without CVD and those with low degrees of
* Corresponding author: Dr C. Heiss, fax +49 211 811 8812, email christian.heiss@med.uni-duesseldorf.de
Abbreviations: BP, blood pressure; CF, cocoa ﬂavanol; DBP; diastolic blood pressure; FMD, ﬂow-mediated dilation; PWV, pulse wave velocity; SBP, systolic
blood pressure.
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cardiovascular risk, that is, healthy subjects, has not been
evaluated. To yield meaningful results, studies aimed at
addressing this point ideally need to be conducted in the con-
text of broader age-range and include both sexes, and they
need to be carried out for durations of 4 weeks or longer(7).
Thus, in the present study, we sought to investigate the effects
of dietary CF intake on established surrogate markers of
cardiovascular risk in healthy, middle-aged individuals without
history, signs or symptoms of CVD. As the primary end point,
we selected to measure endothelial function as ﬂow-mediated
dilation (FMD), and included assessments of plasma lipids, BP
and pulse wave velocity (PWV) as secondary end points. Using
a well-characterised CF-containing test drink and its CF-free
control, we undertook a randomised, double-masked, 1-month
dietary CF intervention assessing the above end points. In
addition, based on applying the Framingham Risk Model we
also aimed at providing an initial evaluation of the potential for
dietary CF in the context of primary CVD prevention.
Methods
Study participants and study design
The study took place at the Division of Cardiology, Pulmonology
and Vascular Medicine of Duesseldorf University in Duesseldorf,
Germany from February 2013 to August 2014. We recruited
subjects by word-to-mouth and by postings at the University and
University Outpatient Clinic. All subjects who came to our
attention were recruited for eligibility screened and consecutively
included if eligible. A total of 114 consecutive subjects underwent
assessment for eligibility (see Fig. 1 for CONSORT diagram). We
included 105 middle-aged (35–60 years) healthy Caucasian male
and female subjects without history, signs or symptoms indicative
of CVD, including previous myocardial infarction (MI), stroke and
peripheral artery disease or current or previous medication, and a
BMI of 23–27 kg/m2 (inclusion criteria). Exclusion criteria were
manifest or suspected CVD, diabetes, kidney failure, acute
inﬂammation or a heart rhythm other than sinus, extreme diets
including vegetarians and vegans, alcoholism and vitamin
supplement use.
We ﬁrst performed an open-label kinetic pilot study in ﬁve
male volunteers. The subjects received 450 mg of CF twice daily
for 1 month to determine the time course of endothelial func-
tion by FMD, which measures endothelial function and is a
prospectively validated surrogate marker of cardiovascular risk.
Subsequently, we performed a 1-month double-masked, ran-
domised, controlled trial in 100 participants who were randomly
(block randomisation) assigned to one of two parallel groups (1:1
ratio of intervention and controls): either the CF intervention
group (FLAVANOL; 450mg of total ﬂavanols twice daily) or the
Assessed for eligibility (n 114)
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Fig. 1. (a) Study flow (CONSORT diagram) and (b) study protocol of the randomised controlled study. BID, twice daily; FMD, flow-mediated dilation; PWV, pulse wave
velocity; AIX, augmentation index.
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CF-free intervention group (CONTROL; 0mg of total ﬂavanols
twice daily). All interventions were provided as drink powder in
sachets to be freshly prepared by mixing with approximately
500ml of water. Drinks were consumed twice a d: one beverage
in the morning with breakfast (06.00–08.00 h) and one with the
evening meal (18.00–20.00 h). We did not require the study
subjects to follow a strict timing. This regimen was maintained for
1 month, with compliance assessed by the collection of empty
sachets on the last study day visit. All measurements were taken
in the fasting state before (‘baseline’) and at 2 h after the ﬁrst
drink on day 1, and at 1 month (day 28–30) again in the fasting
state and at 2 h after consumption of the last drink. Subjects were
asked to refrain from consuming excess amounts of ﬂavanol-rich
foods (list provided to participants) for 24 h before study visits.
No other restrictions before and during intervention regarding
diet and lifestyle were required. FMD was the primary end point.
Secondary pre-speciﬁed end points included ofﬁce BP and
plasma total, LDL and HDL-cholesterol concentration in order to
determine cardiovascular risk parameters according to the
Framingham Risk Prediction model(8). The 10-year risks to
develop CHD or CVD, to experience a MI or stroke or to die from
CHD or CVD were calculated using the Framingham equation
in the Excel calculator (http://cvrisk.mvm.ed.ac.uk/). Further
pre-speciﬁed secondary end points included parameters derived
from pulse wave analysis, including PWV, aortic augmentation
index (AIX), reﬂective of vascular physicomechanics and central
systolic blood pressure (SBP) and diastolic blood pressure (DBP).
A tertiary pre-speciﬁed end point was the total plasma epica-
techin metabolite concentration.
Subjects were asked to follow a 10-min supine rest period
before examinations and to remain in a supine position
throughout the examination, including BP measurements, FMD,
pulse wave analysis and blood draws following the identical
sequence. FMD was measured on the right arm, and BP mea-
surements and blood draws were performed on the left arm.
Participants and investigators were masked throughout the
study with regard to ﬂavanol content of the test drinks, and
intervention drinks were allocated in random order using block
randomisation. As the open-label pilot study had only one arm,
analyses were performed in an observer-blinded manner. The
ethics committee of the Heinrich-Heine University approved the
study protocol, and all subjects gave written informed consent
(Clinicaltrials.gov: NCT01799005).
Test materials
Both interventions used a low-energy fruit-ﬂavoured beverage
mix (provided by Mars Inc.), which was standardised and
matched in composition. All beverage mixes were agglomer-
ated powders with a maltodextrin base into which ﬂavouring
and sweeteners were incorporated. The beverage mixes were
provided in sachets (7 g, equals one serving) labelled with an
alphanumeric identiﬁer to enable a double-masked study
design. A high-ﬂavanol cocoa extract (Cocoapro®-processed
cocoa extract; Mars Inc.) was the source of ﬂavanols in the
CF-containing drink. The CF-containing drink (FLAVANOL)
provided 450mg of total CF per serving(9). The total amount of
CF in mg represents the sum of all monomeric ﬂavanols and
their oligomers (i.e. procyanidins) with a degree of
polymerisation up to and including 10 (i.e. DP 1–10). The
predominant monomeric ﬂavanol in this drink was (−)-epica-
techin (see Table 1). The control beverage mix did not contain
any cocoa extract, and thus it provided 0 mg of CF (CONTROL).
Given the natural presence of theobromine and caffeine in
cocoa extract, both theobromine and caffeine were added to
the control beverage mix in order to match the composition
of alkaloids in the CF-containing test product. Colouring was
also added so that the 0 mg CF CONTROL drink was also
indistinguishable in appearance. Compositional details for the
0 mg (CONTROL) and 450 mg CF (FLAVANOL) test drinks are
provided in Table 1.
Flow-mediated vasodilation and power analysis of the
primary end point
FMD and nitroglycerin-mediated vasodilation (NMD) were
measured in the brachial artery of the right arm using 5-min
forearm occlusion by ultrasound (Vivid I; GE Healthcare) in
combination with a semi-automated analysis system (Brachial
Analyzer; MIA), as described(10). The intra- and inter-individual
variability for FMD measurements established in our laboratory
are 0·9 % (SD of difference between repeated FMD measure-
ments in twenty middle-aged healthy subjects, unpublished)
and 1 % (SD within a group of healthy old subjects)(11). FMD was
deﬁned as the primary outcome. On the basis of previous
intervention studies with CF, we expected a change in FMD by
1·3 %(4). Assuming an SD of change in FMD of 1 %, ﬁfty
experimental and ﬁfty control subjects would provide sufﬁcient
power to detect an absolute change in FMD of 0·6 % (two-sided
α of 5 %, power = 0·80). As we were planning on recruiting
50 % women, we also kept the possibility in mind that women
may respond differently from men. Therefore, it should
be mentioned that under the same conditions twenty-ﬁve
experimental and twenty-ﬁve control subjects would provide
sufﬁcient power to detect an absolute change in FMD of 0·8 %
(two-sided α of 5 %, power= 0·80)(12).
Table 1. Composition of interventional vehicles ingested bi-daily
FLAVANOL CONTROL
Total cocoa flavanols (mg) 450 ND
Monomers (mg) 73 ND
(−)-Epicatechin (mg) 64 ND
(−)-Catechin (mg) 7 ND
(+)-Catechin (mg) 2 ND
(+)-Epicatechin (mg) ND ND
Dimers–decamers (mg) 377 ND
Theobromine (mg) 44 46
Caffeine (mg) 10 6
Fat (mg) 0 0
Carbohydrates (mg) 6000 6000
Protein (mg) 100 100
Energy (kJ) 104·6 104·6
Energy (kcal) 25 25
Na (mg) 3 3
K (mg) 95 85
ND, not detectable.
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Blood pressure measurements
Ofﬁce BP was measured using an automated clinical digital
sphygmomanometer (Dynamap) at the upper left arm in supine
position, after 10 min of rest in a quiet room with the arm at the
heart level. We took three measurements, discarded the
ﬁrst and averaged the second and third for further analysis.
Central BP was derived from peripheral pulse wave analysis
(SphygmoCor®; AtCor-Medical).
Cholesterol and clinical chemistry measurements
All clinical chemistry parameters including total, LDL and
HDL-cholesterol, TAG (enzymatic photometric assay; Roche
Diagnostics), HbA1c, C-reactive protein (quantitative immuno-
turbidimetric assay; Roche Diagnostics), glucose (hexokinase
assay) and whole blood count (ﬂow cytometry; Sysmex) were
measured from yellow and purple top serum vacutainer
tubes using standard techniques by the Institute for Clinical
Chemistry, University Duesseldorf, Germany.
Pulse wave analysis
Central BP parameters including AIX and PWV were measured
in supine subjects by applanation tonometry using the
SphygmoCor® system. By means of a transfer function, the
pressure waveform of the ascending aorta was synthesised.
PWV was determined from measurements taken at the carotid
and femoral artery, as previously described(13).
Estimation of background ﬂavanol intake
Background ﬂavanol intake was assessed using a modiﬁed
version of the EPIC Norfolk(14) FFQ. Flavanol monomer, epi-
catechin and CF intakes were calculated using the Flaviola
Flavanol Food Composition Database(15).
Analysis of ﬂavanols and their metabolites in plasma
(−)-Epicatechin and its related metabolites were analysed in
plasma by HPLC-FLD/UV and electrochemical detection using
authentic standards provided by Mars Inc., as previously
described(16). Before analysis, plasma samples (0·5ml) were
defrosted on ice and then subjected to β-glucuronidase and
sulfatase treatment (2000 U/ml; 40 min; 37°C). Then, samples
were mixed with 2 ml of acidiﬁed ice-cold methanol (0·5 %
acetic acid in methanol, v/v) containing 3′-O-ethyl-(−)-epica-
techin (500 nM) as a recovery standard. Samples were cen-
trifuged at 17 000 g for 15 min at 4°C and the supernatant was
collected. The pellet was extracted again with 2 ml of acidiﬁed
ice-cold methanol (0·5 % acetic acid in methanol, v/v) con-
taining 3′-O-ethyl-(−)-epicatechin (500 nM), and then with 1 ml
of 50 % methanol acidiﬁed with 0·5 % acetic acid and containing
3′-O-ethyl-(−)-epicatechin (500 nM). Combined supernatants
underwent concentration (to approximately 50 µl) using a
Speedvac system (Thermo Fisher Scientiﬁc Inc.) and were
mixed with resorcinol (300 pmol) and catechol (300 pmol)
before analysis by HPLC. Flavanol monomers and O-methylated
metabolites were analysed using a Hewlett-Packard 1200 series
HPLC (Hewlett-Packard) equipped with diode array and
ﬂuorescent detection. Samples (50 µl) were injected onto a
reversed-phase Phenomenex Luna C18(2) column (4·6×150mm)
with 3-µm particle size. The mobile phase consisted of (A)
HPLC-grade water, (B) 200mM Na acetate, pH 4·4/methanol (84/
16) and (C) acetonitrile, and the following gradient protocol was
run: 0min, 75% A, 25% B; 5min, 75 % A, 25% B; 20min, 65% A,
25% B; 28min, 63% A, 25% B; 34min, 55% A; 25% B; 41min,
45 % A, 25% B; 45min, 25% B, 75% C; 55min, 25 % B, 75% C;
56·1min 75% A, 25% B; 60min, 75% A, 25% B. The ﬂow rate
was 0·8ml/min. Detection of ﬂavanols and their metabolites was
performed using a ﬂuorescent detector with an excitation
wavelength of 276 nm and an emission wavelength of 316 nm.
The concentration of each compound was determined using an
external calibration curve produced with the use of authentic
standards.
Statistical methods
The characteristics of the study population are expressed as
mean values and standard deviations. Changes in FMD values
in the pilot study were compared by one-way repeated-
measures ANOVA and are presented as mean values and their
standard error of means. The primary test for an effect in the
RCT was an independent t test comparing the difference
between changes due to FLAVANOL and CONTROL at 1 month.
Mean values of results are presented as mean values and their
standard error of means, and differences between responses are
presented as mean values and 95 % conﬁdence intervals.
Responses to treatments were calculated as changes in
respective parameters (e.g. FMD): 1-month values minus
baseline values on day 1. We also evaluated the difference
between changes at 2 h after acute consumption of intervention
drinks on day 1 and at 1 month as compared with baseline on
day 1. Data not normally distributed are presented as median
(interquartile range), and group differences are compared with
Mann–Whitney U tests. Analyses were computed with SPSS 20
(IBM). Correlations were presented as Pearson’s r.
Results
Baseline characteristics of the healthy study population
None of the 105 subjects had been previously diagnosed with
or had clinical signs or symptoms of CVD. None of the parti-
cipants were on current medical treatment, including medica-
tion, and the baseline demographic parameters were within
normal limits (Table 2). There were no statistically signiﬁcant
differences between the CONTROL and FLAVANOL group with
regard to these parameters. Furthermore, our analysis of FFQ
showed that the estimated intake of ﬂavanols was low, com-
parable to the general European public(15), and there was no
difference between the groups. On the basis of their Framing-
ham Risk Scores, the participants exhibited a low risk – that is,
the 10-year risk to be diagnosed with CHD or to experience a
MI was 3·4 (SD 3·7) % and 1·3 (SD 2·1) %, respectively (n 105).
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The estimated risk to die from CVD over the next 10 years was
0·5 (SD 0·9) %.
The ﬁrst ﬁve subjects recruited were male, and they participated
in the open-label pilot study to (a) verify the efﬁcacy of the
ﬂavanol drink to increase FMD, (b) allow re-assessment of effect
size to power the main study and gain insight into (c) temporal
responses and timing of the main study (Fig. 2). The remaining 100
subjects were included in the main study and randomly assigned
to either FLAVANOL or CONTROL treatment. The test drinks were
well tolerated and not a single adverse event was reported.
Time course of FMD during daily open-label FLAVANOL
consumption over 1 month
We ﬁrst performed an open-label pilot study in ﬁve male volun-
teers, who received 450mg of CF twice daily for 1 month to
determine the time course of FMD, the primary end point of the
main randomised controlled study. FMDmeasurements were taken
in the fasting state before (0 h) and at 1 and 2 h after consumption
of the ﬁrst drink in the morning on days 1, 7, 14, 21 and 28.
As depicted in Fig. 2, the time course identiﬁed an ‘acute’
increase in FMD at 1 and 2 h after consumption of CF and a
‘chronic’ increase in fasting FMD. With bi-daily CF consumption
over weeks, the FMD as measured after overnight fasting (>12 h
after consumption of last intervention drink) increased from day
1 (6·0 (SEM 0·3) %) to day 7 (6·6 (SEM 0·2) %) and again from day 7
to day 14 (7·8 (SEM 0·1) %). At days 21 and 28, we observed
no further increase in the fasting FMD and acute ingestion,
suggesting a saturation of CF-related ‘chronic’ effects (day 21:
8·2 (SEM 0·2) %, day 28: 8·2 (SEM 0·2) %). The change in fasting
FMD between day 1 and day 28 was 2·3 (SD 0·4) %. Although
fasting FMD ‘chronically’ increased, additional ‘acute’ CF
consumption only signiﬁcantly improved FMD at days 1 and 7.
Flavanol intake improves endothelial function
In the 1-month randomised controlled trial, FLAVANOL con-
sumption led to a signiﬁcant improvement in FMD as compared
Table 2. Baseline characteristics of study groups
(Mean values and standard deviations)
FLAVANOL CONTROL
Mean SD Mean SD P *
n 55 50
Male/female 30/25 25/25
Age (years) 45 8 44 9 0·778
BMI (kg/m2) 25 3 26 3 0·310
Height (cm) 180 10 178 7 0·453
Weight (kg) 83 14 82 14 0·579
Creatinine (μmol/l) 71 9 80 18 0·991
Total cholesterol (mmol/l) 4·8 0·9 4·8 1·1 0·564
LDL-cholesterol (mmol/l) 3·0 0·9 3·1 0·9 0·315
HDL-cholesterol (mmol/l) 1·6 0·4 1·5 0·3 0·900
TAG (mmol/l) 1·3 0·4 1·1 0·5 0·104
Fasting plasma glucose (mmol/l) 5·0 0·5 4·8 0·4 0·727
HbA1c (%) 5·4 0·3 5·5 0·4 0·649
SBP (mmHg) 126 14 127 10 0·546
DBP (mmHg) 80 9 79 6 0·811
Heart rate (bpm) 64 9 64 8 0·908
CRP (mmol/l) 0·9 0·3 0·9 0·3 0·692
Hb (mg/l) 143 13 140 20 0·721
Leucocytes (1000/ml) 5·8 0·3 5·5 0·3 0·489
Flavanol monomer intake (mg/d)† 35 43 32 45 0·926
Epicatechin intake (mg/d)† 11 8 10 9 0·781
Cocoa flavanol intake (mg/d)† 106 85 106 82 0·701
CRP, C-reactive protein; DBP, office diastolic blood pressure; SBP, office systolic
blood pressure.
* P value from the unpaired t test.
† Values are medians and interquartile ranges and were analysed using the Mann–
Whitney U test.
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Fig. 2 . Time course of flow-mediated dilation (FMD) during the open-label pilot study. Measurements were taken before (0 h) and at 0, 1 and 2 h after ingestion of the
first intervention drink on days 1, 7, 14, 21 and 28 while consuming the drink twice per d (n 5). Ingestion of a single test drink led to an ‘acute’ increase in FMD on days 1
and 7 (A). Although the FMD value as measured after repeated consumption of the drink increased the ‘chronic effect’ (B), ‘acute-on-chronic’ improvements were no
longer statistically significant at days 14, 21 and 28 during daily consumption (C). * P< 0·05 v. 0 h at the same day, respectively, † P< 0·05 v. 0 h at day 1. Values are
means with their standard errors represented by vertical bars.
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with CONTROL (Table 3). FMD improved by 0·7 % (95 % CI 0·5,
0·9 %) at 2 h and by 1·2 % (95 % CI 1·0, 1·4 %) at 1 month. There
were no differences in baseline FMD between men (5·3 (SEM
0·1) %) and women (5·3 (SEM 0·1) %, P= 0·764 t test). The
baseline diameter of the brachial artery and NMD remained
unaffected by either FLAVANOL or CONTROL.
Flavanol intake lowers blood pressure and decreases
vascular stiffness
The consumption of FLAVANOL over 1 month led to a
signiﬁcant decrease in ofﬁce SBP by 4·4mmHg (95% CI 0·9,
7·9mmHg) and ofﬁce DBP by 3·9mmHg (95% CI 1·1, 6·7mmHg)
as compared with CONTROL (Table 3). Pulse wave analysis
showed that central SBP and DBP responses were similar to
peripheral BP results with signiﬁcant lowering by 4·3mmHg
(95% CI 7·6, 0·8mmHg) and 4·7mmHg (95% CI 1·7, 7·8mmHg),
respectively. PWV and AIX decreased by 0·4m/s (95% CI 0·8,
0·04m/s) and 5·3% (95% CI 2·1, 8·5%) at 1 month of FLAVANOL
as compared with CONTROL. No changes in body weight were
observed.
Flavanol intake decreases total and LDL-cholesterol, but
increases HDL-cholesterol
Both total and LDL-cholesterol signiﬁcantly decreased by
0·20 mmol/l (95 % CI 0·39, 0·01 mmol/l) and 0·17 mmol/l (95 %
CI 0·32, 0·02mmol/l), whereas HDL-cholesterol increased
by 0·10 mmol/l (95 % CI 0·04, 0·17 mmol/l) at 1 month after
FLAVANOL as compared with CONTROL. No signiﬁcant
changes were observed with regard to TAG, fasting plasma
glucose or HbA1c.
Plasma levels of structurally related ﬂavanol metabolites
At the baseline visit (day 1, 0 h), the fasting levels of total
plasma ﬂavanols were below the limit of detection in ninety-
eight subjects. At 2 h after acute consumption of FLAVANOL,
the concentration of structurally related ﬂavanol metabolites
signiﬁcantly increased in plasma (987 nmol/l (95 % CI 857,
1118 nmol/l)) over CONTROL. After 1 month of twice-daily CF
consumption and following overnight fasting, fasting levels
were again in all but seven below the limit of detection.
Additional acute ingestion of FLAVANOL in contrast to
CONTROL led to ﬂavanol plasma concentration increase of
1045 nmol/l (95 % CI 890, 1200 nmol/l), but these levels were
not signiﬁcantly different from values observed after acute
ingestion on day 1 (t test). Whereas ‘acute’ changes in FMD
could be directly related to bioactive ﬂavanol metabolites,
‘chronic’ changes in FMD as measured after overnight fasting
are difﬁcult to directly relate to plasma ﬂavanols, as there were
basically no plasma ﬂavanols detectable in the subjects at this
time point. The mechanism underlying the effects may be
related as judged by the fact that there is no acute effect once a
chronic effect is established after more than 2 weeks of chronic
consumption but are probably different in nature as they persist
after overnight fasting. However, we observed a signiﬁcant
correlation between an increase in FMD and increase in plasma
ﬂavanols at 2 h post consumption (r 0·44, P< 0·0001) and also a
signiﬁcant correlation between ‘chronic’ FMD improvements at
1 month and the acute increase in plasma ﬂavanols at 2 h as an
index of individual ﬂavanol bioavailability (r 0·67, P< 0·0001).
Initial assessments of the impact of ﬂavanol intake on CVD
risk using Framingham Risk Scores
As described above, the study participants were healthy and at
low cardiovascular risk based on their Framingham Risk Scores.
To evaluate the primary preventive potential of ﬂavanols, we
calculated changes in components of the Framingham Risk
Score using the age, the total and HDL-cholesterol and ofﬁce
SBP values (absolute changes are given in Table 3). FLAVANOL
led to signiﬁcant decreases in the estimated 10-year risk to be
diagnosed with CHD (percent decrease relative to baseline:
21 % (95 % CI 8, 33 %)) or CVD (percent decrease: 22 % (95 % CI
8, 36 %)) or experience MI (percent decrease: 31 % (95 % CI 9,
51 %)). The decrease in stroke risk was not statistically sig-
niﬁcant. The predicted 10-year risk to die from CHD or CVD
was lowered (percent decrease: 37 % (95 % CI 17, 56 %) and
30 % (95 % CI 10, 49 %)) by FLAVANOL over CONTROL.
Discussion
Study design and effect size of cocoa ﬂavanol-induced
changes on vascular function
The Flaviola Health study is the ﬁrst randomised controlled trial
to establish the efﬁcacy of CF for improvement of established
parameters of vascular function in healthy middle-aged
individuals. Several features of this study are distinctive in
testing the concept that dietary CF intake can maintain vascular
health: (1) the study cohort consisted of healthy individuals
without any history, signs or symptoms of CVD, and it is
representative for a middle-aged European population with
regard to both general health status and habitual average
ﬂavanol intake(15); (2) vascular function was comprehensively
assessed at the level of conduit and resistance arteries, including
acute and long-term effects, allowing for a comprehensive
characterisation of circulatory function; (3) the study was
undertaken using a randomised, double-masked design, and
based on the use of nutrient-matched and standardised CF-rich
and CF-free drinks, allowing for the mitigation of potentially
confounding effects mediated by other bioactive food
components; (4) a preceding open-label run-in study permitted
reliable re-assessment of effect size and time course, enabling
power analysis and ﬁnal design for the main Flaviola Health
study; and (5) changes in vascular function were measured
along with established surrogates of cardiovascular risk, such as
BP and cholesterol, allowing the assessment of changes in
individual cardiovascular risk scores(7,17). Taken together, this
approach enabled us to test the hypothesis of whether or not CF
intake improves vascular function even in healthy individuals.
In addition, we aimed at assessing the effects of CF in the
context of the maintenance of vascular health – a concept that
gained renewed attention through recent publications by
the American Heart Association(18) and others – and at
evaluating the potential of CF in primary CVD prevention and
public health.
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Table 3. Overview of primary, secondary and tertiary end points
(Mean values with their standard errors; 95% confidence intervals)
FLAVANOL (n·50) CONTROL (n·50)
Baseline 2 h 1 month 1 month, 2 h Baseline 2 h 1 month 1 month, 2 h
Difference Difference Difference at
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM at 2 h* 95% CI at 1 month* 95% CI 1 month, 2 h* 95% CI
Primary end point (%)
FMD 5·3 0·1 6·0 0·1 6·4 0·1 6·8 0·1 5·3 0·1 5·4 0·1 5·3 0·1 5·4 0·1 0·7 0·5, 0·9† 1·2 1·0, 1·4† 1·6 1·3, 1·8†
Secondary end points (mmHg)
Office SBP 126 2 124 2 121 2 121 2 127 1 127 2 126 2 125 2 −1·8 −4·9, 1·2 −4·4 −7·9, −0·9† −4·6 −7·1, −0·1†
Office DBP 79 1 77 1 75 1 76 1 78 1 78 1 78 1 79 1 −2·4 −5·1, 0·2 −3·9 −6·7, −1·1† −3·8 −6·2, −1·3†
Total cholesterol (mmol/l) 4·84 0·13 4·64 0·13 4·79 0·13 4·77 0·10 −0·20 −0·39, −0·01†
LDL-cholesterol (mmol/l) 3·08 0·13 2·90 0·13 3·11 0·13 3·11 0·10 −0·17 −0·32, −0·02†
HDL-cholesterol (mmol/l) 1·53 0·05 1·61 0·05 1·50 0·05 1·48 0·05 0·10 −0·04, 0·17†
PWV (m/s) 7·2 0·2 6·9 0·2 6·8 0·2 6·8 0·2 7·2 0·2 7·2 0·2 7·2 0·2 7·2 0·2 −0·3 −0·6, −0·1† −0·4 −0·8, −0·04† −0·4 −0·7, −0·005†
AIX (%) 17 2 14 2 12 2 10 2 15 2 15 2 15 2 14 2 −3·3 −6·4, −0·3† −5·3 −8·9, −1·6† −5·9 −9·5, −2·3†
Central SBP (mmHg) 118 2 115 2 112 2 113 2 116 2 117 2 116 2 115 2 −2·8 −5·5, −0·2† −5·3 −8·5, −2·1† −3·8 −6·8, −0·7†
Central DBP (mmHg) 80 1 78 1 76 1 76 1 79 1 79 1 79 1 79 1 −2·5 −4·8, −0·8† −4·7 −7·8, −1·7† −4·4 −7·1, −1·7†
10-year CHD risk (%) 3·4 0·5 2·7 0·4 3·4 0·5 3·4 0·5 −0·6 −1·3, −0·3†
10-year MI risk (%) 1·3 0·3 0·9 0·2 1·3 0·3 1·3 0·3 −0·5 −0·8, −1·2†
10-year stroke risk (%) 0·8 0·1 0·6 0·1 0·7 0·1 0·7 0·1 −0·1 −0·2, 0·03†
10-year CVD risk (%) 4·9 0·7 3·9 0·5 4·8 0·7 4·8 0·7 −1·0 −1·7, −0·4†
10-year CHD death risk (%) 0·4 0·1 0·2 0·1 0·4 0·1 0·4 0·1 −0·2 −0·3, −0·004†
10-year CVD death risk (%) 0·5 0·1 0·3 0·1 0·5 0·1 0·5 0·1 −0·2 −0·3, −0·03†
Tertiary end point (nmol/l)
Epicatechin metabolites 4 3 991 64 71 26 1049 76 0‡ 0 0‡ 0 0‡ 0 0‡ 0 987 857, 1118† 68 10, 125† 1045 890, 1200†
AIX, augmentation index; DBP, diastolic blood pressure; FMD, flow-mediated dilation; MI, myocardial infarction; PWV, pulse wave velocity; SBP, systolic blood pressure.
* Differences with CI are from the unpaired t test comparing FLAVANOL with CONTROL changes from baseline.
† 95 % CI does not span zero, indicating significant difference.
‡ Below limit of detection.
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The primary end point of the study was FMD. FMD is a
validated prognostic marker of cardiovascular risk, and an
improvement in 1 % FMD has been associated with a decrease
in overall CVD risk over 3·6 years of 8 %(19). In the present
study, in which we assessed FMD after overnight fast, we
observed a signiﬁcant increase in FMD of 1·2 % after 1 month of
daily CF consumption. Although the 1-month duration of this
study represents one of its limitations, this time frame of
assessing changes in FMD is regarded as clinically relevant(7),
according to the recent EFSA consensus statement on the sci-
entiﬁc requirements for studies aiming at supporting FMD-
based health claims(7). Together with the fact that this study is
the ﬁrst larger-scale ﬂavanol dietary intervention to investigate
healthy populations, we would advance that our data are per-
tinent and meaningful. Generally considering the effect size in
the context of previous interventions with FMD as the primary
end point, which do not thus far include longer-term studies in
healthy individuals, similar degrees of improvement have been
reported for some, but not all, interventions in patients(20),
including the use of ACE inhibitors(21), statins(20,22), as well as
various lifestyle modiﬁcations, including physical exercise
training(23). Taken together, our study suggests that the endo-
thelial functional improvements because of CF intake are similar
in effect size, or even greater, compared with established
primary and secondary preventive strategies(20–22).
Cocoa ﬂavanol intake decreases blood pressure, vascular
stiffness and cholesterol
Throughout middle and old age, BP is strongly and directly
related to cardiovascular (and overall) mortality, without any
evidence of a threshold down to at least 115/75 mmHg(24).
Dividing people into ‘hypertensives’ and ‘normotensives’ is
common practice, but it is problematic as there are now sufﬁ-
cient trial data to show a statistically signiﬁcant risk reduction
when decreasing the BP even in ‘normotensive’ individuals,
without known vascular disease(25). In this context, the risk
reduction is rather due to the decrease in BP per se, and there
seems to be little or no difference between commonly used
BP-lowering medications for primary prevention of CVD(26).
The results in the present study show that CF intake led to a
signiﬁcant decrease in SBP and DBP in healthy individuals. This
decrease in BP was detected in central and peripheral arteries.
The effect size in our current study (a decrease of in-ofﬁce BP of
4·4/3·9 mmHg (SBP/DBP)) was comparable to that described in
a meta-analysis (comparison of CF intake with true CF-free
controls using a blinded study design in patients with CVD or
subjects being at risk for CVD (3·7/2·7mmHg)(5,27)) and
approaches the BP-lowering effect sizes observed by typical
BP-lowering medications(28).
So far, no other study of this scale has addressed whether or
not ﬂavanols can decrease BP in healthy subjects with normal BP
at the beginning of the study. The parallel changes in PWV and
aortic augmentation are consistent with the notion that an
improved elasticity of arteries or arterial unloading may be
related to SBP lowering. The strong association between ageing
and increases in PWV as a marker for vascular stiffness supports
that PWV is a marker of vascular age(29). In our study, the PWV
signiﬁcantly decreased toward values that are usually seen in
persons several years younger. The parallel changes in central
BP and AIX suggest that this may have positive effects on cardiac
function. Future studies will have to verify the biological
relevance of such ﬁndings in the context of longer-term investi-
gations and characterise the mechanisms involved. In the context
of the present study, we cannot mechanistically dissect whether
or not the CF intake-induced change in PWV may be primarily
caused by a softening of the aorta and large vessels or are
secondary to alterations in cardiac stroke volume, changes in
central and peripheral BP or because of alterations in the total
peripheral resistance. (We have addressed the effect of CF on
haemodynamics in much more detail in a recent study(30).)
In middle- and old age, and at all BP levels, high plasma
cholesterol is positively associated with IHD mortality(31).
Depending on age, a decrease in total cholesterol of 1 mmol/l
was associated in middle-aged individuals with a decreased risk
of IHD mortality by 50%. We here show in healthy volunteers
that CF may be able to decrease total and LDL-cholesterol by
0·2mmol/l over 1 month. A meta-analysis investigating the effects
of cocoa products on lipids in diverse populations suggested an
overall total and LDL-cholesterol-lowering effect of 0·2mmol/l
but no signiﬁcant effect on HDL-cholesterol(32). Overall, these
outcomes were conﬁrmed by a more recent meta-analysis
including fourteen studies(4). The results differed from the
ﬁrst meta-analysis(32) in so far as they demonstrated a small, but
signiﬁcant, increase in HDL-cholesterol in longer-term studies(4),
which is consistent with our current study, thus supporting that CF
may be capable of improving blood lipids in healthy volunteers.
Primary prevention, cardiovascular health and dietary
guidelines
By applying the Framingham framework of risk assessment to
our data set, it can be demonstrated that our study population
was indeed healthy and at low risk for CHD (which is deﬁned as
a 10-year risk to develop CHD of <10%, compared with 3·4% in
the present study). More importantly, it can be estimated that CF
intake has the potential to reduce the 10-year risk of CV
morbidity and mortality even in this healthy cohort by 20–30 %
and 30–40 % (percent relative to baseline value), respectively.
Naturally, such estimates would be based on the assumption that
outcomes in terms of efﬁcacy and safety would persist over years
of chronic CF consumption. Thus, although the application
of Framingham risk scoring in this context should be interpreted
with some caution, as our study was limited with regard to
scope and duration, the outcomes of this assessment provide a
useful basis for initial assessments of the potential of
CF in the context of primary CVD prevention, and for data
interpretations and discussions in the light of potential future
studies.
Conclusion
The outcomes of the Flaviola Health study, a CF-based dietary
intervention trial in healthy middle-aged men and women,
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demonstrate improvements in accredited surrogates of cardiovas-
cular risk, including indices of vascular function and metabolism.
Our ﬁndings support the notion that CF intake has the potential to
support the maintenance of cardiovascular health. Furthermore,
our data add to the accumulating body of evidence regarding the
health beneﬁts of dietary ﬂavanols and procyanidins in general,
thus contributing to evidence-based assessments of potential future
dietary guidelines for these bioactives.
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